Elizabeth M. Anderson net worth and biography

Elizabeth Anderson Biography and Net Worth

Director of Insmed

Ms. Anderson has been a member of our board since November 2018, bringing more than 30 years of leadership in biotechnology, pharmaceuticals, and vaccines. Ms. Anderson held senior leadership positions at Johnson & Johnson between 2003 and her retirement in 2014. She most recently served as Worldwide Vice President, Infectious Disease and Vaccines for Janssen Pharmaceuticals, a Johnson & Johnson company, where she directed the commercial development of an extensive portfolio of antivirals and vaccines with responsibility for global strategic marketing, market access, and global analytics for that division. Prior to Johnson & Johnson, Ms. Anderson served as the Vice President and General Manager of Wyeth Lederle Vaccines from 1997 to 2002. She also previously worked at Rhone Poulenc Rorer and the American National Red Cross. Ms. Anderson serves on the boards of directors of the private company Aro Biotherapeutics Inc. and the public companies GSK plc, Revolution Medicines, Inc., and BioMarin Pharmaceutical Inc. She holds a Bachelor of Science degree in Engineering from Rutgers University and a Master of Business Administration degree from Loyola University Maryland. Ms. Anderson is chair of the Nominations & Governance Committee.

What is Elizabeth M. Anderson's net worth?: The estimated net worth of Elizabeth M. Anderson is at least $11.57 million as of November 24th, 2025. Ms. Anderson owns 58,729 shares of Insmed stock worth more than $11,570,200 as of December 12th. This net worth estimate does not reflect any other assets that Ms. Anderson may own. Learn More about Elizabeth M. Anderson's net worth.
How do I contact Elizabeth M. Anderson?: The corporate mailing address for Ms. Anderson and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected]. Learn More on Elizabeth M. Anderson's contact information.
Has Elizabeth M. Anderson been buying or selling shares of Insmed?: In the last ninety days, Elizabeth M. Anderson has sold $2,981,600.00 of Insmed stock. Most recently, Elizabeth M. Anderson sold 5,000 shares of the business's stock in a transaction on Monday, November 24th. The shares were sold at an average price of $204.58, for a transaction totalling $1,022,900.00. Following the completion of the sale, the director now directly owns 58,729 shares of the company's stock, valued at $12,014,778.82. Learn More on Elizabeth M. Anderson's trading history.
Who are Insmed's active insiders?: Insmed's insider roster includes Roger Adsett (COO), Elizabeth Anderson (Director), Sara Bonstein (CFO), David Brennan (Director), Clarissa Desjardins (Director), Clarissa Desjardins (Director), Martina Flammer (Insider), Leo Lee (Director), William Lewis (CEO), David McGirr (Director), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.
Are insiders buying or selling shares of Insmed?: In the last year, Insmed insiders bought shares 2 times. They purchased a total of 3,025 shares worth more than $201,694.15. In the last year, insiders at the biopharmaceutical company sold shares 74 times. They sold a total of 1,482,921 shares worth more than $149,825,544.11. The most recent insider tranaction occured on November, 24th when Director Elizabeth M Anderson sold 5,000 shares worth more than $1,022,900.00. Insiders at Insmed own 3.0% of the company. Learn More about insider trades at Insmed.
Information on this page was last updated on 11/24/2025.

Elizabeth M. Anderson Insider Trading History at Insmed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/24/2025	Sell	5,000	$204.58	$1,022,900.00	58,729
11/14/2025	Sell	10,000	$195.87	$1,958,700.00	63,729

Elizabeth M. Anderson Buying and Selling Activity at Insmed

Insmed Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Range

Now: $197.01

$191.74

$198.13

50 Day Range

MA: $185.10

$158.28

$211.41

2 Week Range

Now: $197.01

$60.40

$212.75

Volume

1,781,017 shs

Average Volume

2,741,582 shs

Market Capitalization

$42.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01